JP2022519407A - 外科的移植のための生体組織を調製する方法 - Google Patents
外科的移植のための生体組織を調製する方法 Download PDFInfo
- Publication number
- JP2022519407A JP2022519407A JP2020573519A JP2020573519A JP2022519407A JP 2022519407 A JP2022519407 A JP 2022519407A JP 2020573519 A JP2020573519 A JP 2020573519A JP 2020573519 A JP2020573519 A JP 2020573519A JP 2022519407 A JP2022519407 A JP 2022519407A
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- biological tissue
- biological
- living tissue
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002054 transplantation Methods 0.000 title claims description 19
- 210000001519 tissue Anatomy 0.000 claims abstract description 195
- 238000000034 method Methods 0.000 claims abstract description 73
- 210000003516 pericardium Anatomy 0.000 claims abstract description 30
- 210000003709 heart valve Anatomy 0.000 claims abstract description 28
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 90
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 73
- 241000283690 Bos taurus Species 0.000 claims description 45
- 239000000243 solution Substances 0.000 claims description 44
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 30
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical group O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 15
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 239000003431 cross linking reagent Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 239000007789 gas Substances 0.000 claims description 8
- 239000002504 physiological saline solution Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 239000012266 salt solution Substances 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 230000002308 calcification Effects 0.000 abstract description 21
- 238000010586 diagram Methods 0.000 abstract 1
- 208000004434 Calcinosis Diseases 0.000 description 21
- 239000000463 material Substances 0.000 description 20
- 102000008186 Collagen Human genes 0.000 description 18
- 108010035532 Collagen Proteins 0.000 description 18
- 229920001436 collagen Polymers 0.000 description 18
- 238000001000 micrograph Methods 0.000 description 13
- 210000004379 membrane Anatomy 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000011575 calcium Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000012890 simulated body fluid Substances 0.000 description 8
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 230000000872 anti-mineralization Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 210000005003 heart tissue Anatomy 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 238000004626 scanning electron microscopy Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000003570 air Substances 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000004334 sorbic acid Substances 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 239000004218 Orcein Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000012080 ambient air Substances 0.000 description 2
- 210000001765 aortic valve Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000002473 artificial blood Substances 0.000 description 2
- 238000001479 atomic absorption spectroscopy Methods 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000033558 biomineral tissue development Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000003102 pulmonary valve Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical group N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000004775 Tyvek Substances 0.000 description 1
- 229920000690 Tyvek Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003715 calcium chelating agent Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000705 flame atomic absorption spectrometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 208000018578 heart valve disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000001724 microfibril Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000004115 mitral valve Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000879 optical micrograph Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000000591 tricuspid valve Anatomy 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3625—Vascular tissue, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
- A61L2/186—Peroxide solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/20—Gaseous substances, e.g. vapours
- A61L2/206—Ethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
- A61L27/3687—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by the use of chemical agents in the treatment, e.g. specific enzymes, detergents, capping agents, crosslinkers, anticalcification agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/02—Treatment of implants to prevent calcification or mineralisation in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/20—Materials or treatment for tissue regeneration for reconstruction of the heart, e.g. heart valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking
Abstract
Description
(1)架橋剤で処理された生体組織に生理食塩溶液を含浸させる工程と、
(2)含浸された生体組織を、過酸化水素を含む水溶液と接触させる工程と、
(3)生体組織をPBS及びEDTAを含む水溶液と接触させる工程と、
(4)生体組織をグリセロール、エタノール及びEDTAを含む溶液と接触させる工程と、
(5)生体組織をグリセロール溶液と接触させる工程と、
を含む、方法が提供される。
ウシ心膜「sample 180702-1」(P+F Brasil社、EDQM認定)から選択された1×1cmの生体組織を含む40枚のメンブレンを、最初に0.625%のグルタルアルデヒド溶液(P+F GmbH社/Biocollagen)から取り出し、その後に冷えた0.9%の生理食塩溶液(JP Pharma社)中で3分間含浸させた。次いで、含浸された組織を0.5容量%の過酸化水素(Sigma-Aldrich社)中に18℃で60分間浸漬させた。次の工程として、該組織を、冷えた(10℃)PBS(pH7.4)及び0.5重量%のEDTAと3分間接触させた(Sigma-Aldrich社)。その後に、該組織を、激しく撹拌しながら22℃の温度で60秒間、99容量%のエタノール(Sigma-Aldrich社)中に浸漬させた後に、ゆっくりと撹拌しながら22℃の温度で60分間、グリセロール/エタノール(50/50)及び0.5重量%のEDTA(Sigma-Aldrich社)の混合物中に浸漬させた。さらに、該組織を、ゆっくりと撹拌しながら22℃の温度で120分間、99%のグリセロール(Sigma-Aldrich社)中に浸漬させた。次に、該組織を、激しく撹拌しながら22℃の温度で60秒間、99容量%の無水エタノール(Sigma-Aldrich社)及び0.5重量%のEDTAで含浸させた。最後に、該組織に、HEPAフィルターを通した空気を通気しながら18℃の温度で18時間、溶剤蒸発の処置を行う。次に、該組織を二重のタイベック製パウチに包み、Sterium社(Sterium Company)でETO滅菌(55℃、4時間のETO曝露)した。
ウシ心膜「sample 180702-2」から選択された1×1cmの生体組織を含む40枚のメンブレンを、実施例1-1に記載される手順に従って調製した。
ウシ心膜「sample 180803-1」から選択された1×1cmの生体組織を含む40枚のメンブレンを、0.625%のグルタルアルデヒド溶液(P+F GmbH社/Biocollagen)から取り出し、更に処理をせずに比較試料として使用した。
実施例1-1~実施例1-3からのウシ心膜メンブレン(試料の番号:180702-2及び180702-1は本発明によるものであり、180803-1は比較例である)を生理食塩溶液中で2分間含浸させた後に、表3に示されるようにヒト血漿と同様のイオン濃度を有する溶液である擬似体液(SBF)中に浸漬させ、同じ生理的条件のpH及び温度(pH7.4及び温度36.5℃)で維持した。浸漬時間は1日から30日の間で変化させた。
ウシ心膜(P+F Brasil社)から選択され、グルタルアルデヒド(Sigma-Aldrich社、0.625容量%)の存在下で固定された75単位の生体組織を、冷えた0.9%の生理食塩溶液(JP Farma社)中に置き、その後にpH7.4のPBS(Sigma-Aldrich社)及びEDTA(Sigma-Aldrich社、0.2重量%)を含む水溶液中に3分間置き、引き続きエタノール(Sigma-Aldrich社、70容量%)ですすいだ。次いで、含浸された組織を周囲温度で約1分間エタノール中に浸漬させた。次の工程として、該組織をグリセロール(Sigma-Aldrich社、99%)、エタノール及びEDTA溶液の混合物(70%のグリセロール、29.8%のエタノール及び0.2%のEDTA溶液)と周囲温度で少なくとも90分間接触させた。その後に、該組織を撹拌しながら少なくとも90分間グリセロール中に浸漬させ、引き続きエタノールですすいだ。次いで、該組織を溶液から慎重に取り出し、空気で乾燥させた。16時間の乾燥後に、該組織を再水和及び機械的安定性に関して調べた。
ウシ心膜(P+F Brasil社)から選択され、グルタルアルデヒド(Sigma-Aldrich社、0.625容量%)の存在下で固定された04(130mmの直径を有する円形の4つのパッチ)単位の生体組織を、冷えた0.9%の生理食塩溶液(JP Farma社)中に置き、その後にpH7.4のPBS(Sigma-Aldrich社)及びEDTA(Sigma-Aldrich社、0.2重量%)を含む水溶液中に3分間置き、引き続きエタノール(Sigma-Aldrich社、70容量%)ですすいだ。次いで、含浸された組織を周囲温度で約1分間エタノール中に浸漬させた。次の工程として、該組織をグリセロール(Sigma-Aldrich社、99%)、エタノール及びEDTA溶液の混合物(70%のグリセロール、29.8%のエタノール及び0.2%のEDTA溶液)と周囲温度で少なくとも90分間接触させた。その後に、該組織を撹拌しながら少なくとも90分間グリセロール中に浸漬させ、引き続きエタノールですすいだ。これらの試料を、原子吸光分析ContrAA 300(Analytik Jena社、ドイツ、イエナ)にかけた。表2は、標準的なグルタルアルデヒド保存されたウシ心膜に対するこれらの試料のカルシウム含有量を示している。
染剤を使用した組織学的評価によってコラーゲン線維の完全性を調査して、ウシ心膜試料における乾燥過程後のコラーゲン線維の保存を調べた。Eclipse E-200(株式会社ニコン)と一緒にフルデジタルビデオHD Lite 1080p(Tucsen社)を使用して画像を取得した。結果を標準的なグルタルアルデヒド保存された材料試料と比較した。図4(乾燥させたウシ心膜)及び図5(標準的なウシ心膜)に示される種々の染剤を使用して検査を行った。ここで、HEはヘマトキシリンを意味し、REはレゾルシン-オルセインを意味し、TMはマッソントリクロームを意味し、TGはゴモリトリクロームを意味する(全ての染剤はMerck社により供給された)。
標準的なウシ心膜及び乾燥したウシ心膜(両方)のコラーゲン構造及び乾燥過程の抗石灰化効果を、種々の分解能を使用して走査型電子顕微鏡法(SEM、FESEM、JEOL社、モデル7500F)によって評価した:
(a)乾燥させたウシ心膜:図6:倍率200倍、図7:倍率3000倍、図8:倍率50000倍、図9:倍率100000倍;
(b)標準的なウシ心膜:図10:倍率200倍、図11:倍率3000倍、図12:倍率50000倍、図13:倍率100000倍。
Claims (15)
- 生体組織を処理する方法であって、
(1)架橋剤で処理された生体組織に生理食塩溶液を含浸させる工程と、
(2)前記含浸された生体組織を、過酸化水素を含む水溶液と接触させる工程と、
(3)前記生体組織をPBS及びEDTAを含む水溶液と接触させる工程と、
(4)前記生体組織をグリセロール、エタノール及びEDTAを含む溶液と接触させる工程と、
(5)前記生体組織をグリセロール溶液と接触させる工程と、
を含む、方法。 - 前記生体組織を少なくとも70容量%の濃度内のエタノールと接触させる工程(3a)及び/又は工程(5a)を更に含む、請求項1に記載の方法。
- 前記架橋剤はグルタルアルデヒドである、請求項1又は2に記載の方法。
- 前記生体組織は、ウシ又はブタの心膜又は心臓弁である、請求項1~3のいずれか一項に記載の方法。
- 前記生理食塩溶液は、0.9%の塩化ナトリウムを含む水溶液である、請求項1~4のいずれか一項に記載の方法。
- 工程(4)におけるグリセロール:エタノールの容量比は、1:5~5:1である、請求項1~5のいずれか一項に記載の方法。
- 工程(3)及び工程(4)におけるEDTAは、0.01重量%~10.0重量%の濃度を有する、又は工程(2)における過酸化水素は、0.05容量%~5.0容量%の濃度を有する、請求項1~6のいずれか一項に記載の方法。
- 前記生体組織を乾燥させる工程(6)と、前記生体組織をパッケージ中に入れる工程(7)と、前記パッケージを密封する工程(8)と、前記パッケージを滅菌する工程(9)とを更に含む、請求項1~7のいずれか一項に記載の方法。
- 前記生体組織を含むパッケージの滅菌は、前記パッケージをエチレンオキシドガスに曝露することによって実施される、請求項8に記載の方法。
- 前記工程(1)~前記工程(5)は10℃~25℃の温度で実施され、特に前記工程(6)及び前記工程(7)は、10℃~25℃の温度で実施される、請求項1~9のいずれか一項に記載の、特に請求項8に記載の方法。
- 前記工程(4)及び前記工程(5)は、撹拌しながら少なくとも60分間実施される、請求項1~10のいずれか一項に記載の方法。
- 請求項1~11のいずれか一項に記載の方法に従って調製された生体組織を含む生体組織。
- 外科的移植のための、請求項12に記載の生体組織の使用。
- 生体補綴物としての、請求項12に記載の生体組織の使用。
- 経カテーテル心臓弁における、請求項12に記載の生体組織の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19155986.3A EP3693030A1 (en) | 2019-02-07 | 2019-02-07 | Method for preparing biological tissue for surgical implantation |
EP19155986.3 | 2019-02-07 | ||
PCT/EP2020/053001 WO2020161243A1 (en) | 2019-02-07 | 2020-02-06 | Method for preparing biological tissue for surgical implantation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022519407A true JP2022519407A (ja) | 2022-03-24 |
JP7448491B2 JP7448491B2 (ja) | 2024-03-12 |
Family
ID=65363163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020573519A Active JP7448491B2 (ja) | 2019-02-07 | 2020-02-06 | 外科的移植のための生体組織を調製する方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220072202A1 (ja) |
EP (2) | EP3693030A1 (ja) |
JP (1) | JP7448491B2 (ja) |
KR (1) | KR20210124886A (ja) |
CN (1) | CN112236175A (ja) |
BR (1) | BR112020023977A2 (ja) |
WO (1) | WO2020161243A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113423363A (zh) * | 2020-11-13 | 2021-09-21 | P+F产品功能公司 | 自膨式支架和支架组 |
EP4046600A1 (en) * | 2021-02-18 | 2022-08-24 | P+F Products + Features GmbH | Aortic stent |
EP4046602A1 (en) * | 2021-02-18 | 2022-08-24 | P+F Products + Features GmbH | Self-extendable stent for pulmonary artery |
KR20230041362A (ko) | 2021-09-17 | 2023-03-24 | 주식회사 엘지에너지솔루션 | 전지셀의 임피던스 측정 충방전지그 |
CN114209886B (zh) * | 2021-11-09 | 2022-12-02 | 江苏臻亿医疗科技有限公司 | 一种生物组织材料及其制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3835237C1 (ja) | 1988-10-15 | 1989-12-28 | B. Braun Melsungen Ag, 3508 Melsungen, De | |
WO1999058082A2 (en) | 1998-05-14 | 1999-11-18 | The Cleveland Clinic Foundation | Processing of implantable animal tissues for dry storage |
JP2002531181A (ja) | 1998-12-01 | 2002-09-24 | クック・バイオテック・インコーポレーテッド | 多型コラーゲン性バイオマテリアル医療装置 |
US6479079B1 (en) | 1999-12-13 | 2002-11-12 | Sulzer Carbomedics Inc. | Anticalcification treatments for fixed biomaterials |
CA2563648C (en) | 2004-04-20 | 2013-11-19 | Regeneration Technologies, Inc. | Process and apparatus for treating implants |
JP4503356B2 (ja) | 2004-06-02 | 2010-07-14 | 東京エレクトロン株式会社 | 基板処理方法および半導体装置の製造方法 |
US20060095021A1 (en) | 2004-11-02 | 2006-05-04 | Casas-Bejar Jesus W | Introduction of agent with medical device |
CN101626682B (zh) | 2006-10-27 | 2014-04-16 | 爱德华兹生命科学公司 | 用于外科植入的生物组织 |
EP3028672A1 (en) | 2010-03-01 | 2016-06-08 | Colibri Heart Valve LLC | Percutaneously deliverable heart valve and method associated therewith |
EP2542668A2 (en) | 2010-03-01 | 2013-01-09 | Colibri Heart Valve LLC | Tissue for prosthetic implants and grafts, and methods associated therewith |
CN102946916B (zh) * | 2010-06-17 | 2015-03-18 | 爱德华兹生命科学公司 | 通过化学修饰抗原性碳水化合物稳定生物假体组织的方法 |
CA2864050A1 (en) | 2012-03-22 | 2013-09-26 | Trb Chemedica International S.A. | Method for repair of ligament or tendon |
CN103432627B (zh) * | 2013-08-26 | 2015-03-25 | 北京瑞健高科生物科技有限公司 | 一种制备动物脱细胞组织基质材料的方法及其制备的组织基质材料 |
CN106190949B (zh) | 2015-05-08 | 2020-04-10 | 上海微创心通医疗科技有限公司 | 一种干态动物源性胶原纤维组织材料及其制备方法和生物假体 |
US10722613B2 (en) * | 2017-06-29 | 2020-07-28 | St. Jude Medical, Cardiology Division, Inc. | Method of preparing calcification-resistant bioprosthetic tissue |
-
2019
- 2019-02-07 EP EP19155986.3A patent/EP3693030A1/en not_active Withdrawn
-
2020
- 2020-02-06 US US17/428,760 patent/US20220072202A1/en active Pending
- 2020-02-06 EP EP20702807.7A patent/EP3765105A1/en active Pending
- 2020-02-06 KR KR1020207036453A patent/KR20210124886A/ko active Search and Examination
- 2020-02-06 BR BR112020023977-1A patent/BR112020023977A2/pt unknown
- 2020-02-06 CN CN202080002849.6A patent/CN112236175A/zh active Pending
- 2020-02-06 JP JP2020573519A patent/JP7448491B2/ja active Active
- 2020-02-06 WO PCT/EP2020/053001 patent/WO2020161243A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN112236175A (zh) | 2021-01-15 |
EP3693030A1 (en) | 2020-08-12 |
JP7448491B2 (ja) | 2024-03-12 |
US20220072202A1 (en) | 2022-03-10 |
WO2020161243A1 (en) | 2020-08-13 |
EP3765105A1 (en) | 2021-01-20 |
KR20210124886A (ko) | 2021-10-15 |
BR112020023977A2 (pt) | 2021-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7448491B2 (ja) | 外科的移植のための生体組織を調製する方法 | |
CA2666485C (en) | Biological tissue for surgical implantation | |
CA2817732C (en) | Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability | |
US9211361B2 (en) | Thin collagen tissue for medical device applications | |
WO2018167536A1 (en) | Implantable material and method for preserving | |
JP2017502750A (ja) | 無細胞コラーゲン組織及び無細胞コラーゲン組織を含む人工弁膜の処理方法 | |
JPH04501077A (ja) | ウシ心膜材料の調製方法およびその用途 | |
US20060110370A1 (en) | Treatments for reduction of cytotoxicity and viral contamination of implantable medical devices | |
EP3952936A1 (en) | A process for prevention of degradation and degeneration of tissue used in bioprosthesis | |
US20220331488A1 (en) | Prosthetic Tissue Treatment For Desirable Mechanical Properties | |
CN111359020B (zh) | 软组织修复材料及其制备方法和应用 | |
EP2550029A1 (en) | Thin collagen tissue for medical device applications | |
EP2772274A1 (en) | Method for treating animal-derived collagen fibre materials | |
AU773150B2 (en) | A method using potassium dihydrogen phosphate to reduce calcification of tissue | |
US9555162B2 (en) | Phospholipid reduction in biological tissue | |
WO2000074692A1 (en) | A method using potassium dihydrogen phosphate to reduce calcification of tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20201225 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221129 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230817 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230829 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231128 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240206 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240229 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7448491 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |